STOCK TITAN

Silexion keeps Nasdaq listing subject to conditions

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Nasdaq’s Hearings Panel granted Silexion Therapeutics Corp. (SLXN) continued listing on the Nasdaq Capital Market, subject to conditions. By November 24, 2026, the company must demonstrate compliance with the minimum bid-price requirement by maintaining a closing bid price of at least $1.00 per share for at least ten consecutive trading days. By December 4, 2026, it must complete its planned private placement for net proceeds of $2.5 million and demonstrate compliance with the $2.5 million minimum shareholders’ equity requirement, including through a balance sheet dated no more than 60 days before the applicable SEC filing.

By March 31, 2027, the company must complete a planned public offering of at least $5 million and maintain compliance with all Nasdaq listing requirements through May 15, 2027. Failure to meet a requirement during that period, other than the existing deficiencies addressed by the conditions, results in immediate delisting. Silexion had effected a 1-for-24 reverse share split on November 10, 2026, effective for trading November 11, and said there can be no assurance it will meet the conditions or regain or maintain compliance.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointContinued listing granted subject to conditions

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Failures outside specified deficiencies trigger immediate delisting
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Minimum shareholders’ equity requirement $2.5 million Nasdaq requirement; compliance must be demonstrated by December 4, 2026.
Planned private placement net proceeds $2.5 million The company must complete the planned placement by December 4, 2026.
Minimum closing bid price $1.00 per share Must be maintained for at least ten consecutive trading days by November 24, 2026.
Required bid-price period At least 10 consecutive trading days Condition for demonstrating compliance with Nasdaq’s minimum bid-price requirement by November 24, 2026.
Planned public offering At least $5 million Must be completed by March 31, 2027.
Nasdaq compliance deadline May 15, 2027 Silexion is required to maintain compliance with all Nasdaq listing requirements through this date.
Balance sheet age limit No more than 60 days Balance sheet supporting the equity-compliance demonstration must be dated no more than this period before the applicable SEC filing.
Reverse share split ratio 1-for-24 Silexion effected the split on November 10, 2026; it became effective for trading November 11, 2026.
Nasdaq Capital Market regulatory
"continued listing on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
minimum shareholders’ equity requirement regulatory
"the $2.5 million minimum shareholders’ equity requirement"
minimum bid price requirement regulatory
"compliance with the minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
closing bid price financial
"maintaining a closing bid price of at least $1.00 per share"
The closing bid price is the last price that a buyer was willing to pay for a security at the end of the trading day. It reflects the final visible demand for the stock — like the last offer someone makes for a used car before a yard closes — and helps investors gauge market interest, set valuations, and mark portfolios to market for that day.
net proceeds financial
"private placement financing for net proceeds of $2.5 million"
The amount of money a company actually keeps from a sale or fundraising after paying all direct costs and fees, similar to take-home pay after taxes and deductions. Investors care because net proceeds determine how much cash is available for things that affect value—paying debt, funding projects, buying assets, or returning money to shareholders—so it influences future growth potential and financial health.
reverse share split technical
"effected a 1-for-24 reverse share split"
A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What must SLXN do to remain listed on Nasdaq?

SLXN must meet the panel’s financing and bid-price conditions: complete a planned private placement for net proceeds of $2.5 million by December 4, 2026; demonstrate a closing bid price of at least $1.00 per share for at least ten consecutive trading days by November 24, 2026; and complete a planned public offering of at least $5 million by March 31, 2027. It must maintain Nasdaq listing compliance through May 15, 2027.

What happens if SLXN fails to meet a Nasdaq listing requirement?

Failure to meet a requirement outside the existing deficiencies being addressed results in immediate delisting during the period in which Silexion is required to maintain Nasdaq listing compliance through May 15, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0002022416 00-0000000 0002022416 2026-11-19 2026-11-19 0002022416 us-gaap:CommonStockMember 2026-11-19 2026-11-19 0002022416 SLXN:WarrantsExercisableForOrdinarySharesMember 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 19, 2026 (November 18, 2026)

 

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-42253   N/A
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)       Identification No.)

 

12 Abba Hillel Road

Ramat-Gan, Israel

  5250606
(Address of principal executive offices)   (Zip Code)

 

+972-3-7564999

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $3.24 per share   SLXN   The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $372,600.00 per share   SLXNW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 8.01 Other Events.

 

Outcome of Nasdaq Hearings Panel; Continued Listing

 

On November 18, 2026, Silexion Therapeutics Corp. (the “Company”) received a favorable decision from a Nasdaq Hearings Panel granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the conditions described below. The decision followed the Company’s appeal of Nasdaq’s August 18, 2026 delisting determination relating to the Company’s non-compliance with the $2.5 million minimum shareholders’ equity requirement and also addressed the Company’s non-compliance with Nasdaq’s $1.00 minimum bid price requirement.

 

In its final form, the Panel’s decision requires the Company to: (i) by December 4, 2026, complete its planned private placement financing for net proceeds of $2.5 million and demonstrate compliance with, and its ability to maintain compliance with, the minimum shareholders’ equity requirement, including through a balance sheet dated no more than 60 days prior to the applicable SEC filing; (ii) by November 24, 2026, demonstrate compliance with the minimum bid price requirement by maintaining a closing bid price of at least $1.00 per share for at least ten consecutive trading days; and (iii) by March 31, 2027, complete a planned public offering of at least $5 million.

 

The Company is also required to maintain compliance with all Nasdaq listing requirements through May 15, 2027. Failure to comply with any Nasdaq listing requirement during this period, other than the existing deficiencies being addressed pursuant to the foregoing conditions, will result in immediate delisting.

 

As previously reported, in furtherance of its efforts to regain compliance with the minimum bid price requirement, the Company effected a 1-for-24 reverse share split on November 10, 2026, which became effective for trading purposes on November 11, 2026.

 

There can be no assurance that the Company will satisfy the conditions imposed by the Panel or otherwise regain or maintain compliance with the applicable Nasdaq continued listing requirements.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. Those statements include, without limitation, those related to: the Company’s ability to complete its planned private placement financing and restore compliance with the minimum shareholders’ equity requirement by the December 4, 2026 deadline; the Company’s ability to demonstrate compliance with the minimum bid price requirement by November 24, 2026; the Company’s ability to complete its planned public offering of at least $5.0 million by March 31, 2027; the Company’s ability to maintain compliance with all Nasdaq listing rules through May 15, 2027; and all other statements that are not historical facts. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Current Report on Form 8-K, including, but not limited to, that: the Company may not be successful in completing the steps required of it to maintain its Nasdaq listing in the timeframe required by the Panel’s decision; and the Company may encounter other difficulties in maintaining compliance with all Nasdaq listing standards through May 15, 2027, which would result in the immediate delisting of its securities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026. Those filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise those forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SILEXION THERAPEUTICS CORP
   
Date: November 19, 2026 /s/ Ilan Hadar
  Name: Ilan Hadar
  Title: Chief Executive Officer

 

 

Filing Exhibits & Attachments

4 documents

Keep reading